STOCK TITAN

Petvivo Holdings, Inc. and PiezoBioMembrane Inc. Announce Master Services Agreement to Jointly Develop Innovative Functional Biomaterials

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
PetVivo Holdings and PiezoBioMembrane have entered into a Master Services Agreement to develop innovative functional biomaterials. The collaboration combines PetVivo's expertise in extracellular matrix (ECM) biomaterials with PiezoBio's piezoelectric nanofibers technology. The partnership aims to create biomaterials that can be biologically activated through piezoelectric stimulation to enhance healing and regeneration of damaged tissue and bone in animals and humans. PetVivo's current product SPRYNG® with OsteoCushion® Technology demonstrates their capability in creating biocompatible materials that mimic mammalian tissue. PiezoBio contributes their biodegradable piezoelectric nanomaterial technology, which functions as a battery-less electrical stimulator to promote enhanced cell activity in implanted tissue or bone.
PetVivo Holdings e PiezoBioMembrane hanno stipulato un Master Services Agreement per sviluppare biomateriali funzionali innovativi. La collaborazione unisce l'esperienza di PetVivo nei biomateriali a matrice extracellulare (ECM) con la tecnologia dei nanofibre piezoelettriche di PiezoBio. L'obiettivo della partnership è creare biomateriali che possano essere attivati biologicamente tramite stimolazione piezoelettrica, migliorando la guarigione e la rigenerazione di tessuti e ossa danneggiati in animali e esseri umani. Il prodotto attuale di PetVivo, SPRYNG® con tecnologia OsteoCushion®, dimostra la loro capacità di realizzare materiali biocompatibili che imitano i tessuti dei mammiferi. PiezoBio contribuisce con la sua tecnologia di nanomateriale piezoelettrico biodegradabile, che funziona come uno stimolatore elettrico senza batteria per favorire una maggiore attività cellulare nei tessuti o nelle ossa impiantate.
PetVivo Holdings y PiezoBioMembrane han firmado un Acuerdo Marco de Servicios para desarrollar biomateriales funcionales innovadores. La colaboración combina la experiencia de PetVivo en biomateriales de matriz extracelular (ECM) con la tecnología de nanofibras piezoeléctricas de PiezoBio. La asociación tiene como objetivo crear biomateriales que puedan activarse biológicamente mediante estimulación piezoeléctrica para mejorar la curación y regeneración de tejidos y huesos dañados en animales y humanos. El producto actual de PetVivo, SPRYNG® con tecnología OsteoCushion®, demuestra su capacidad para crear materiales biocompatibles que imitan el tejido mamífero. PiezoBio aporta su tecnología de nanomaterial piezoeléctrico biodegradable, que funciona como un estimulador eléctrico sin batería para promover una mayor actividad celular en tejidos u huesos implantados.
PetVivo Holdings와 PiezoBioMembrane은 혁신적인 기능성 생체재료 개발을 위해 마스터 서비스 계약을 체결했습니다. 이번 협력은 PetVivo의 세포외기질(ECM) 생체재료 전문성과 PiezoBio의 압전 나노섬유 기술을 결합합니다. 이 파트너십은 압전 자극을 통해 생물학적으로 활성화될 수 있는 생체재료를 만들어 동물과 인간의 손상된 조직 및 뼈의 치유와 재생을 촉진하는 것을 목표로 합니다. PetVivo의 현재 제품인 SPRYNG® with OsteoCushion® 기술은 포유류 조직을 모방하는 생체 적합성 재료를 만드는 역량을 보여줍니다. PiezoBio는 배터리가 필요 없는 전기 자극기로 작용하는 생분해성 압전 나노재료 기술을 제공하여 이식된 조직이나 뼈에서 세포 활동을 증진합니다.
PetVivo Holdings et PiezoBioMembrane ont conclu un Master Services Agreement pour développer des biomatériaux fonctionnels innovants. Cette collaboration associe l'expertise de PetVivo en biomatériaux de matrice extracellulaire (ECM) à la technologie des nanofibres piézoélectriques de PiezoBio. Le partenariat vise à créer des biomatériaux pouvant être activés biologiquement par stimulation piézoélectrique afin d'améliorer la guérison et la régénération des tissus et os endommagés chez les animaux et les humains. Le produit actuel de PetVivo, SPRYNG® avec la technologie OsteoCushion®, démontre leur capacité à créer des matériaux biocompatibles imitant les tissus des mammifères. PiezoBio apporte sa technologie de nanomatériau piézoélectrique biodégradable, qui fonctionne comme un stimulateur électrique sans batterie pour favoriser une activité cellulaire accrue dans les tissus ou os implantés.
PetVivo Holdings und PiezoBioMembrane haben eine Master Services Agreement abgeschlossen, um innovative funktionale Biomaterialien zu entwickeln. Die Zusammenarbeit verbindet PetVivos Expertise in extrazellulären Matrix (ECM) Biomaterialien mit der piezoelektrischen Nanofaser-Technologie von PiezoBio. Ziel der Partnerschaft ist es, Biomaterialien zu schaffen, die durch piezoelektrische Stimulation biologisch aktiviert werden können, um die Heilung und Regeneration von geschädigtem Gewebe und Knochen bei Tieren und Menschen zu verbessern. PetVivos aktuelles Produkt SPRYNG® mit OsteoCushion® Technologie zeigt ihre Fähigkeit, biokompatible Materialien zu entwickeln, die das Gewebe von Säugetieren nachahmen. PiezoBio bringt seine biologisch abbaubare piezoelektrische Nanomaterial-Technologie ein, die als batterieloser elektrischer Stimulator fungiert und die Zellaktivität im implantierten Gewebe oder Knochen fördert.
Positive
  • Strategic partnership combines complementary technologies in biomaterials and piezoelectric materials
  • Potential to develop new therapeutic products for tissue and bone regeneration
  • Battery-free, wireless self-stimulated technology for tissue regeneration
  • Expansion into new therapeutic applications beyond current product lines
Negative
  • Development timeline and costs not specified
  • No guarantee of successful product development or commercialization
  • Regulatory approval requirements not addressed

MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively referred to herein as the "Company" or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for animals, and PiezoBioMembrane, Inc (“PiezoBio”)., a pioneer in biodegradable piezoelectric materials intended for implantable applications, today announced a transformative Master Services Agreement. The strategic partnership centers on collaborative research and development of revolutionary functional biomaterials that include piezoelectric nanofibers incorporated into a biocompatible biomaterial comprised of natural materials that mimics mammalian extracellular matrix (“ECM”). We believe these functional biomaterials can be biologically activated by piezoelectric stimulation to promote regeneration and/or remodeling of damaged or injured tissue and bone in animals and humans.

Partnership Structure and Strategic Benefits

Under the Master Services Agreement, PetVivo and PiezoBio will collaboratively work to combine PetVivo’s ECM biomaterial with PiezoBio’s piezoelectric nanofibers. The anticipated piezo-biomaterial derived from this collaboration is intended to have functional attributes that can be biologically activated, thereby promoting enhanced healing, regeneration and/or remodeling of damaged or injured mammalian tissue and bone.

PetVivo has developed and is commercializing a biocompatible biomaterial that mimics mammalian tissue. The Company has recognized the many advantages of matching the composition of implantable biomaterials to the native tissue surrounding the implant site and the importance of creating biomatrix materials that exhibit limited to no adverse effects when placed in the body of an animal or human. PetVivo has successfully created a biomaterial that is included in several new product lines that possess these assimilating and biocompatible properties.

One example of PetVivo’s biocompatible, ECM-like products is SPRYNG® with OsteoCushion® Technology. Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

Mike Eldred, Board Member of PetVivo Holdings, Inc. said, "PetVivo has been developing the next-generation of biomaterials that mimic mammalian tissue using all-natural components, which are commonly found in the extracellular matrix of animals and humans. We aim to leverage our in-house biomaterial expertise, along with the exceptional piezoelectric material expertise of PiezoBio, to develop the next generation of functional biomaterials. This collaboration with PiezoBio will enable us to advance our research and potentially result in innovative medical devices and therapeutics that can be transformative for veterinarians and their patients."

PiezoBio has developed a biodegradable piezoelectric nanomaterial that can act as a battery-less electrical stimulator to promote enhanced cell activity when implanted in mammalian tissue or bone. The technology provides, for the first time, (1) a wireless, battery-free and self-stimulated technology to generate electrical stimulation for inducing tissue/bone regeneration, (2) a tool to systematically study interaction between cells and surface charge for tissue/bone regeneration, and (3) an approach to design and create a novel nanomaterial-based biodegradable piezoelectric scaffold which can form highly-regenerative replacement for treatment of damaged or injured tissue and bone.

"We expect that this collaboration will generate synergy by combining PetVivo's experience in developing biocompatible biomaterials made from natural materials and our expertise in piezoelectric materials that promote therapeutic healing and regeneration," said Linh Le, Chief Executive Officer at PiezoBioMembrane, Inc. "Through open innovation, we aim to actively expand our development efforts beyond our core areas related to piezoelectric materials to enhanced functional biomaterials that may be used in a multitude of therapeutic fields."

For more information about PetVivo Holdings, Inc. and our revolutionary products, Spryng with OsteoCushion Technology and PrecisePRP, please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ or http://www.sprynghealth.com.

For more information about PiezoBioMembrane, Inc. and our revolutionary piezoelectric material platform, please contact hello@piezo.bio or visit https://www.piezo.bio.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG with OsteoCushion technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216

About PiezoBioMembrane, Inc.

PiezoBio is engaged in the research, development, and manufacturing of piezoelectric biomaterials for healthcare applications. The company is committed to harnessing innovative science and technology to deliver impactful solutions that advance both human and animal health. As a spin-off from the University of Connecticut, PiezoBio pursues strategic partnerships to accelerate product development and reduce time-to-market.

CONTACT:

Linh Le, CEO
PiezoBioMembrane, Inc.
Email: hello@piezo.bio

Forward-Looking Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


FAQ

What is the purpose of the PETV and PiezoBioMembrane partnership?

The partnership aims to develop innovative functional biomaterials by combining PetVivo's ECM biomaterial with PiezoBio's piezoelectric nanofibers to promote enhanced healing and regeneration of damaged tissue and bone in animals and humans.

How does PetVivo's SPRYNG technology work in veterinary applications?

SPRYNG is an intra-articular injectable device with sterilized ECM microparticles that adsorb onto joint synovial lining and integrate with subsynovial tissue, helping manage joint pain and osteoarthritis by restoring proper joint mechanics.

What is unique about PiezoBioMembrane's technology in the PETV partnership?

PiezoBio's technology provides a wireless, battery-free piezoelectric nanomaterial that generates electrical stimulation to promote tissue/bone regeneration when implanted, without requiring external power sources.

What are the potential applications of the PETV-PiezoBio collaborative biomaterials?

The biomaterials could be used for healing and regeneration of damaged or injured tissue and bone in both veterinary and human medical applications, with potential expansion into multiple therapeutic fields.
Petvivo Hldgs Inc

OTC:PETV

PETV Rankings

PETV Latest News

PETV Stock Data

11.43M
11.62M
51.36%
0.77%
Medical Devices
Healthcare
Link
United States
Edina